Objectives. To assess the time trends in prescription opioids detected in fatally injured drivers.
P
rescription opioids (e.g., oxycodone, hydrocodone, and methadone) are potent drugs clinically used to manage pain, suppress substance withdrawal symptoms, and help induce insensitivity to pain during surgery. 1, 2 In the past 2 decades, the distribution and consumption of prescription opioids has increased markedly in the United States. 3 Annual prescriptions of opioids quadrupled from 76 million in 1991 to nearly 300 million in 2014, and an estimated 3900 people initiated nonmedical prescription opioid use daily. 4, 5 As a result, opioid abuse and overdose has become a national public health crisis. Prescription opioids can cause drowsiness, nausea, and impaired cognition and interfere with psychomotor functioning. 6 They may also impair reaction time, alertness, attention, and concentration during driving. 1, [7] [8] [9] Hence driving under the influence of prescription opioids is a serious safety concern. Currently, about one third of fatally injured drivers in the United States test positive for nonalcohol drugs, including prescription opioids, and 20% test positive for 2 or more drugs. 10 Although toxicological testing data indicate a general increase in involvement of nonalcohol drugs in fatal motor vehicle crashes, there is a paucity of evidence for the effect of the opioid epidemic on driving safety in the United States. Results from studies examining the effects of prescription opioids on driving safety are inconsistent. Some experimental studies have found that long-term and stable therapeutic doses of prescription opioids have no measurable effect on driving ability, 7, 11, 12 although increases in dosage may result in significant cognitive impairment that may adversely affect driving safety. 13, 14 A recent review of experimental studies concluded that prescription opioid use may significantly impair psychomotor functions. 15 Most observational studies, particularly those a decade old and older, have reported a nonsignificant association between prescription opioid use and crash risk. 16, 17 Conversely, recent epidemiological studies have found that driver opioid use is associated with significantly increased risks of fatal crash involvement among drivers of all ages [18] [19] [20] [21] [22] [23] [24] and crash culpability in older adult drivers. 25 The conflicting findings between recent studies and older studies might be owing in part to changes in the prevalence of opioid use in the driver population over the past 2 decades.
We assessed the time trends in prescription opioids detected in drivers who died within an hour of a motor vehicle crash in 6 states in the United States that routinely tested driver fatalities for drugs.
METHODS
We obtained data from the Fatality Analysis Reporting System (FARS), which is compiled by the National Center for Statistics and Analysis of the National Highway Traffic Safety Administration. The FARS is a census of fatal motor vehicle crashes that occur on public traffic ways in all 50 states plus the District of Columbia and Puerto Rico from 1975 to the present. 26, 27 Key data include detailed information on the vehicle type, individuals involved, and crash circumstances and results in a fatality (occupant or nonoccupant) within 30 days of the crash. 26, 27 These data are obtained from a variety of sources such as police reports; death certificates; vehicle registration and driver licensing files; coroner, medical, emergency services, and hospital reports; and vital statistics. 27 FARS analysts collect, code, and enter crash information according to standardized protocols. A rigorous quality control program that includes checks for errors, consistency, and completeness ensures data integrity. 27 Data elements include driver characteristics such as age, gender, and alcohol and drug testing data. In 1991, the FARS started to collect toxicological testing data for nonalcohol drugs. Because of incomplete testing and reporting, toxicological testing results for nonalcohol drugs are available for only 30% of all fatally injured drivers nationwide. 26, 27 However, 6 states have performed drug testing on at least 80% of fatally injured drivers between January 1, 1995, and December, 31, 2015.
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Study Sample
The study sample included drivers who died within 1 hour of a motor vehicle crash in 6 states (CA, HI, IL, NH, RI, WV) that conducted toxicological testing for nonalcohol drugs on more than 80% of all fatally injured drivers between January 1, 1995, and December 31, 2015.
During the study period, there were 78 193 drivers involved in 51 924 fatal motor vehicle crashes in the 6 states. Excluded from the analysis were 38 704 drivers who survived more than an hour after the crash, 19 drivers whose survival time after the crash was unknown, and 2741 drivers for whom toxicological testing data were not available. We excluded drivers who survived more than an hour after the crash from the analysis because toxicological testing data for these drivers might not be accurate and reliable because of incomplete testing (only 69.5% of them were tested), false negatives resulting from metabolism, and false positives from medications administered after the crash. Consequently, we included 36 729 drivers who died within 1 hour of the crash and for whom toxicological testing data were available in the study.
Drug Testing Assessments and Measures
Toxicological drug tests were conducted on blood or urine specimens using liquidgas chromatography, mass spectrometry, and radioimmunoassay techniques. 27, 28 Overall, 92.9% of all drivers studied had at least 1 drug test on the basis of blood specimens. Each driver was tested for the presence of up to 3 nonalcohol drugs. In cases in which multiple nonalcohol drugs were detected, FARS records drugs in the following order: narcotics, depressants, stimulants, marijuana, and other drugs. [27] [28] [29] [30] The prescription opioids we analyzed fall under narcotics (first priority), which Prescription opioids included in the operational definition were injectable or oral formulations of fentanyl, hydrocodone, oxycodone, morphine, oxymorphone, methadone, propoxyphene, hydromorphone, meperidine, diphenoxylate, and codeine. 29 Most prescription opioids, such as codeine, oxycodone, morphine, and hydrocodone, have an elimination half-life of 1 to 4 hours and a detection period of 24 hours or less. 31 We referred to nonopioid narcotics, depressants (excluding alcohol), stimulants, and marijuana as other nonalcohol drugs. Blood alcohol concentrations were measured in grams per deciliter, and we considered blood alcohol concentrations of 0.01 grams per deciliter or greater to be alcohol positive.
28,29
Statistical Analysis
We tabulated the prevalence of any opioid alone, in combination with another nonalcohol drug, or in combination with alcohol among drivers who died within 1 hour of the crash by year, driver age, and gender. Furthermore, we computed and plotted the prevalence of specific types of opioids (e.g., hydrocodone, morphine, and oxycodone) over time.
We used the Cochran-Armitage test for trend to assess the statistical significance of changes in the prevalence of prescription opioids over time. We performed all data analyses using SAS version 9.4 (SAS Institute, Inc., Cary, NC).
RESULTS
Drivers who were tested for drugs were more likely to be male (77.8% vs 74.4%; P < .001), slightly younger (mean age = 39.7 621.3 years vs 43.2 626.4 years; P < .001), and less likely to have been involved in a crash in the previous 3 years (15.1% vs 16.6%; P = .034) than were drivers who were not tested. Drivers who died within 1 hour of the crash were slightly younger than were those who survived more than an hour after the crash (mean age = 38.4 620.8 years vs 40.0 621.7 years; P < .001). But the 2 groups did not differ significantly in other characteristics.
Of Figure 1 ). The increase was statistically significant in all age groups and in 4 of the 6 states (CA, IL, NH, WV; Figures 2 and 3) .
The prevalence of prescription opioids was higher in female drivers than in male drivers (4.4% vs 2.9%; P < .001). The prevalence of prescription opioids increased from 0.9% during 1995-1999 to 5.2% during 2010-1015 in male drivers and from 1.4% to 7.3% in female drivers; the increase was statistically significant for both genders (Table 1) . During the study period, the prevalence of prescription opioids in combination with alcohol and other nonalcohol drugs also increased significantly in both genders (Table 1) . Overall, 30.0% of the drivers testing positive for prescription opioids had elevated blood alcohol concentrations, and 66.9% were positive for other drugs.
DISCUSSION
Our results indicate that the prevalence of prescription opioids detected in drivers who were fatally injured within 1 hour of the crash has increased 700% since 1995. In particular, hydrocodone, oxycodone, and morphine have been the most frequently detected prescription opioids. The prevalence of polydrug use involving opioids and alcohol or other nonalcohol drugs also significantly increased over the study period. These findings are a cause of concern because of the increase in prescription opioid use in the general population 4 and the side effects of opioids that may impair driving safety.
The marked increase in the prevalence of prescription opioids detected in fatally injured drivers during the study period accords with the time trends of prescription opioid consumption in the general population 5 and is germane to current drug monitoring programs and best practices regarding opioid prescriptions to patients who drive. Patients on pharmacologically stable opioid doses are recommended to drive only if they abstain from other impairment-inducing medications or substances and if they are free of severe pain, sleep disorders, daytime somnolence, and psychiatric conditions. 32 However, there is a paucity of studies to properly establish the level of doses that might be regarded as stable for each type of opioid. Practice guidelines recommend that clinicians discuss the effects that opioids may have on the ability to safely drive, especially when opioids are initiated, when the dosage changes, or when other substances or drugs are involved.
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However, primary care providers often report insufficient training in prescribing opioids, often worry about opioid abuse, and find managing patients with chronic pain stressful.
Currently, all states and the District of Columbia have operational prescription drug monitoring programs (PDMPs) that monitor, collect, and report opioid prescription and dispensary data. 34 Oversight of the PDMPs varies from boards of pharmacy, departments of health, and law enforcement agencies. Although the effect of PDMPs on opioid prescription misuse and overdose mortality has been studied extensively, little is known about the effectiveness of PDMPs in reducing driving under the influence of opioids and opioid involvement in motor vehicle crashes. In light of the increasing prevalence of prescription opioids detected in fatally injured drivers, evaluation research on the PDMP and other intervention programs aimed at reducing opioid abuse should consider expanding the outcome measures to include drugged driving and opioid involvement in traffic injuries. Additional epidemiologic studies are needed to assess the role of specific types and doses of opioids (such as hydrocodone, oxycodone, and morphine) in crash causation.
Limitations
This study has several notable limitations. First, opioid positivity in toxicological testing may indicate recent use of opioids but does not necessarily imply opioid-induced impairment. The detection window for opiates is 24 hours or less in blood and 1 to 4 days in urine. 30 Second, to enhance internal validity, we restricted the study to 6 states that routinely performed toxicological testing on fatally injured drivers. Therefore, our results may not be directly generalizable to other states. The combined population from the 6 states constituted 18% of the US population, and the death rate from opioid overdose for these 6 states combined in 2007 (9.2 deaths per 100 000 population) was comparable to the national rate (9.9 deaths per 100 000 population). 35 Third, this study was limited to drivers who died within 1 hour of the crash. Although restricting the analysis to these drivers may have helped enhance the internal validity of the study findings, it may have further reduced the generalizability of the results to other drivers (e.g., those involved in nonfatal crashes) and other road users (e.g., pedestrians and bicyclists). Finally, toxicological testing protocols may vary from state to state. Of the 6 states included in the study, 3 (NH, RI, WV) have statewide medical examiner systems and 3 (CA, HI, IL) have mixed medical examiner and coroner systems. 35 Stratified analysis revealed that the prevalence of prescription opioids and the time trends in the prevalence between the 2 groups of states were similar.
Conclusions
During 1995 to 2015, there has been a 7-fold increase in the prevalence of prescription opioids detected in drivers who died within 1 hour of the crash in California, Hawaii, Illinois, New Hampshire, Rhode Island, and West Virginia. The prevalence of prescription opioids is higher in women than in men. Hydrocodone, oxycodone, and morphine are the most commonly detected prescription opioids. Further research is warranted to assess the role of prescription opioids in motor vehicle crashes and the effectiveness of PDMPs and other intervention programs in reducing drugged driving and traffic injuries. 
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